Phase 1 Two Stage Randomized, Double-blind, Placebo Controlled Dose- and Schedule Ranging Trial to Assess the Acute Safety, Tolerability, and Immunogenicity of a Live, Attenuated Shigella/ETEC Combination Vaccine Delivered Orally to Healthy Adults Age 18 to 45 Years Old
Latest Information Update: 13 Jun 2022
Price :
$35 *
At a glance
- Drugs Escherichia coli/Shigella oral vaccine-Eveliqur Biotechnologies (Primary)
- Indications Traveller's diarrhoea
- Focus Adverse reactions; First in man
- Sponsors Eveliqure Biotechnologies
- 23 Feb 2022 According to an Eveliqure Biotechnologies media release, results of this study were published in the peer-reviewed journal Vaccines
- 23 Feb 2022 Results published in the an Eveliqure Biotechnologies Media Release
- 23 Feb 2022 According to an Eveliqure Biotechnologies media release, Status changed from planning to completed.